JPRN-UMIN000004694已完成2 期
Conversion therapy of Cetuximab plus FOLFIRI followed by Bevacizumab plus mFOLFOX6 in patients with liver metastatic colorectal cancer - N-SOG 04
agoya Surgical Oncology Group0 个研究点目标入组 50 人开始时间: 2010年12月10日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Severe myelosuppression (2)Diarrhea(watery) (3)Require treatment of serious infection (4)Uncontrolled body cavity fluid (5)Comorbidity or history of interstitial lung disease or pulmonary fibrosis (6)Severe hypersensitivity (7)Renal failure or urine protein >=+2 within 1 week before enrollment (8)Uncontrollable hypertension or diabetes (9)Significant abnormal ECG or history of cardiovascular disease within 1year (10)Thrombosis with present or history of thromboembolism within 1year (11)Intestinal bleeding, ileus, bowel obstruction or peptic ulcer (12)Perforation of gastrointestinal tract within 1year (13)Administrated with Aspirin (>=325mg/day) or steroid for rheumatoid arthritis and chronic inflammatory disease (14)Pregnant and lacting woman,woman with suspected pregnancy, and men of the fertility hope (15)Have anti-thrombosis drugs within 7days before enrollment (16)Need to treatment with Atazanavir sulfate (17)Active multiple cancers (18)Severe mental illness (19)Treated continuously with systemic steroids (20)Any subject judged by the investigator to be unfit for any reason to participate in the study
研究者
相似试验
已完成
2 期
Phase IIstudy of biweekly FOLFIRI+cetuximab treatment for unresectable KRAS-wild type colorectal cancerunresectable colorectal cancerJPRN-UMIN000011363Dept of Surgical Oncology Osaka City University Graduate School of Medicine20
进行中（未招募）
1 期
Avelumab added to FOLFIRI plus Cetuximab followed by Avelumab maintenance in patients with previously untreated RAS wild-type colorectal cancer - The phase II FIRE-6-Avelumab studyAvelumab added to FOLFIRI plus cetuximab followed by avelumab maintenance in patients with previously untreated RAS/BRAF wild-type metastatic colorectal cancer - the phase II FIRE-6-avelumab studyMedDRA version: 21.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2018-002010-12-DEKlinikum der Ludwig-Maximilians-Universität München - Klinikum Großhadern (vertreten durch den kaufmännischen Direktor)55
已完成
2 期
Phase II study of FOLFIRI + cetuximab as induction chemotherapy followed by FOLFIRI + bevacizumab based on early tumor shrinkage in chemotherapy-naive patients with RAS wild-type colorectal cancerColorectal cancerJPRN-UMIN000023026Department of Clinical Oncology, St. Marianna University School of Medicine54
已完成
2 期
Study of Cetuximab to Treat Gastric CancerGastric CancerNCT00699881Fudan University61
招募中
2 期
PhaseII study of Combination FOLFIRI with Cetuximab in patients with advanced/metastatic colorectal cancer previously received oxaliplatin-based chemoterapy.Colorectal CancerJPRN-UMIN000007372Kurume University School of medicine, Department of Surgery30